News headlines about Innoviva (NASDAQ:THRX) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Innoviva earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.8076718315434 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Innoviva (THRX) remained flat at $9.81 on Thursday. Innoviva has a 12 month low of $6.36 and a 12 month high of $21.16. The company has a 50 day moving average price of $9.81 and a 200 day moving average price of $11.67.

COPYRIGHT VIOLATION WARNING: “Innoviva (THRX) Earns News Sentiment Score of 0.12” was first published by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at

Innoviva Company Profile

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Insider Buying and Selling by Quarter for Innoviva (NASDAQ:THRX)

Receive News & Ratings for Innoviva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.